AVSOLA®

AVSOLA® is a biosimilar of the biologic medicine Remicade® (infliximab). Your doctor may prescribe AVSOLA® to treat your chronic inflammation disease.

Administration and Dosage:

For patients with incomplete response, consider increasing maintenance dose to 10 mg/kg every 8 weeks or treating as often as once every 4 weeks (bearing in mind that risk of serious infections increases with higher doses per infusion or more frequent dosing).

Common Side Effects:

Patients treated with infliximab products are at increased risk for developing serious infections that may lead to hospitalization or death and Adverse Reactions. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

More Information:

Please see full Prescribing Information and Medication Guide including Patient Information.

Ready to Schedule an Appointment?

Please CLICK HERE to get started.

Indication:

AVSOLA® is indicated for:

  • Crohn’s Disease: Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy.
  • Pediatric Crohn’s Disease: Reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age or older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy.
  • Ulcerative Colitis: Reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.
  • Pediatric Ulcerative Colitis: Reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.
  • Rheumatoid Arthritis in combination with methotrexate: Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
  • Ankylosing Spondylitis: Reducing signs and symptoms in adult patients with active ankylosing spondylitis.
  • Psoriatic Arthritis: Reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients with psoriatic arthritis.
  • Plaque Psoriasis: The treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.

Follow Us On Instagram